Ident. | Authors (with country if any) | Title |
---|
000083 |
Daniel Weintraub [États-Unis] ; Eugenia Mamikonyan [États-Unis] ; Kimberly Papay [États-Unis] ; Judith A. Shea [États-Unis] ; Sharon X. Xie [États-Unis] ; Andrew Siderowf [États-Unis] | Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale |
000214 |
Michele Poletti [Italie] ; Giulio Perugi [Italie] ; Chiara Logi [Italie] ; Anna Romano [Italie] ; Paolo Del Dotto [Italie] ; Roberto Ceravolo [Italie] ; Giuseppe Rossi [Italie] ; Pasquale Pepe [Italie] ; Liliana Dell'Osso [Italie] ; Ubaldo Bonuccelli [Italie] | Dopamine Agonists and Delusional Jealousy in Parkinson's Disease: A Cross-Sectional Prevalence Study |
000307 |
Roger Kurlan [États-Unis] ; Giovanna Crespi [États-Unis] ; Barbara Coffey [États-Unis] ; Kirsten Mueller-Vahl [Allemagne] ; Stephen Koval [États-Unis] ; Glen Wunderlich [Canada] | A Multicenter Randomized Placebo-Controlled Clinical Trial of Pramipexole for Tourette's Syndrome |
000351 |
Vibeke Guldbrand Rasmussen [Danemark] ; Karen Stergaard [Danemark] ; Erik Dupont [Danemark] ; Steen Hvitfeldt Poulsen [Danemark] | The Risk of Valvular Regurgitation in Patients with Parkinson's Disease Treated with Dopamine Receptor Agonists |
000361 |
Klaus Seppi ; Daniel Weintraub ; Miguel Coelho ; Santiago Perez-Lloret ; Susan H. Fox ; Regina Katzenschlager ; Eva-Maria Hametner ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Christopher G. Goetz ; Cristina Sampaio | The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the Non-Motor Symptoms of Parkinson's Disease |
000362 |
Susan H. Fox [Canada] ; Regina Katzenschlager [Autriche] ; Shen-Yang Lim [Malaisie] ; Bernard Ravina [États-Unis] ; Klaus Seppi [Autriche] ; Miguel Coelho [Portugal] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Christopher G. Goetz [États-Unis] ; Cristina Sampaio [Portugal] | The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the Motor Symptoms of Parkinson's Disease |
000409 |
Claudia Trenkwalder [Allemagne] ; Bryan Kies [Afrique du Sud] ; Monika Rudzinska [Pologne] ; Jennifer Fine [Afrique du Sud] ; Janos Nikl [Hongrie] ; Krystyna Honczarenko [Pologne] ; Peter Dioszeghy [Hongrie] ; Dennis Hill [États-Unis] ; Tim Anderson [Nouvelle-Zélande] ; Vilho Myllyla [Finlande] ; Jan Kassubek [Allemagne] ; Malcolm Steiger [Royaume-Uni] ; Marco Zucconi [Italie] ; Eduardo Tolosa [Espagne] ; Werner Poewe [Autriche] ; Erwin Surmann [Allemagne] ; John Whitesides [États-Unis] ; Babak Boroojerdi [Allemagne] ; Kallol Ray Chaudhuri [Royaume-Uni] | Rotigotine Effects on Early Morning Motor Function and Sleep in Parkinson's Disease: A Double-Blind, Randomized, Placebo-Controlled Study (RECOVER) |
000457 |
Atbin Djamshidian [Royaume-Uni] ; Francisco Cardoso [Brésil] ; Donald Grosset [Royaume-Uni] ; Henrietta Bowden-Jones [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Pathological Gambling in Parkinson's Disease-A Review of the Literature |
000468 |
Cristina Sampaio [Portugal] ; Juliana Bronzova [Pays-Bas] ; Robert A. Hauser [États-Unis] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Serge V. Van De Witte [Pays-Bas] ; Ad Theeuwes [Pays-Bas] | Pardoprunox in Early Parkinson's Disease: Results from 2 Large, Randomized Double-Blind Trials |
000512 |
Olivier Rascol [France] ; Andres Lozano [Canada] ; Matthew Stern [États-Unis] ; Werner Poewe [Autriche] | Milestones in Parkinson's Disease Therapeutics |
000555 |
Maria Milenkova [Allemagne, Bulgarie] ; Bahram Mohammadi [Allemagne] ; Katja Kollewe [Allemagne] ; Christoph Schrader [Allemagne] ; Anja Fellbrich [Allemagne] ; Matthias Wittfoth [Allemagne] ; Reinhard Dengler [Allemagne] ; Thomas F. Münte [Allemagne] | Intertemporal Choice in Parkinson's Disease |
000867 |
Sean S. O'Sullivan [Royaume-Uni] ; Andrew H. Evans [Australie] ; Niall P. Quinn [Royaume-Uni] ; Andrew D. Lawrence [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Reckless Generosity in Parkinson's Disease |
000873 |
Robert A. Hauser [États-Unis] ; Anthony H. V. Schapira [Royaume-Uni] ; Olivier Rascol [France] ; Paolo Barone [Italie] ; Yoshikuni Mizuno [Japon] ; Laurence Salin [France] ; Monika Haaksma [Autriche] ; Nolwenn Juhel [France] ; Werner Poewe [Autriche] | Randomized, Double-Blind, Multicenter Evaluation of Pramipexole Extended Release Once Daily in Early Parkinson's Disease |
000928 |
Olivier Rascol [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France] ; Anne-Marie Bonnet [France] ; Christine Brefel-Courbon [France] ; Pierre Cesaro [France] ; Philippe Damier [France] ; Bérengère Debilly [France] ; Frank Durif [France] ; Monique Galitzky [France] ; Jean-Marie Grouin [France] ; Sylvie Pennaforte [France] ; Gabriel Villafane [France] ; Sadek Yaici [France] ; Yves Agid [France] | Orodispersible Sublingual Piribedil to Abort OFF Episodes: A Single Dose Placebo-Controlled, Randomized, Double-Blind, Cross-Over Study |
000A13 |
Sean S. O'Sullivan [Royaume-Uni] ; Atbin Djamshidian [Royaume-Uni, Autriche] ; Zeshan Ahmed [Royaume-Uni] ; Andrew H. Evans [Australie] ; Andrew D. Lawrence [Royaume-Uni] ; Janice L. Holton [Royaume-Uni] ; Tamas Revesz [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Impulsive-Compulsive Spectrum Behaviors in Pathologically Confirmed Progressive Supranuclear Palsy |
000A30 |
Mario Coletti Moja [Italie] | Hiccups Associated with Non-Ergoline Dopamine Agonists in Parkinson's Disease |
000A86 |
Olivier Rascol [France] ; Paolo Barone [Italie] ; Robert A. Hauser [États-Unis] ; Yoshikuni Mizuno [Japon] ; Werner Poewe [Autriche] ; Anthony H. V. Schapira [Royaume-Uni] ; Laurence Salin [France] ; Mandy Sohr [Allemagne] ; Catherine Debieuvre [France] | Efficacy, Safety, and Tolerability of Overnight Switching from Immediate- to Once Daily Extended-Release Pramipexole in Early Parkinson's Disease |
000A99 |
Juliana Bronzova [Pays-Bas] ; Cristina Sampaio [Portugal] ; Robert A. Hauser [États-Unis] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Ad Theeuwes [Pays-Bas] ; Serge V. Van De Witte [Pays-Bas] ; Guus Van Scharrenburg [Pays-Bas] | Double-Blind Study of Pardoprunox, a New Partial Dopamine Agonist, in Early Parkinson's Disease |
000C13 |
Santiago Perez-Lloret [France] ; Emmanuelle Bondon-Guitton [France] ; Olivier Rascol [France] ; Jean-Louis Montastruc [France] | Adverse Drug Reactions to Dopamine Agonists: A Comparative Study in the French Pharmacovigilance Database |
000D20 |
Luigi M. Romito [Italie] ; Maria Fiorella Contarino [Italie] ; Nicola Vanacore [Italie] ; Anna Rita Bentivoglio [Italie] ; Massimo Scerrati [Italie] ; Alberto Albanese [Italie] | Replacement of Dopaminergic Medication with Subthalamic Nucleus Stimulation in Parkinson's Disease : Long-Term Observation |
000F08 |
Vincenzo Rizzo [Italie] ; Irene Arico [Italie] ; Claudia Mastroeni [Italie] ; Francesca Morgante [Italie] ; Giovanna Liotta [Italie] ; Paolo Girlanda [Italie] ; Rosalia Silvestri [Italie] ; Angelo Quartarone [Italie] | Dopamine Agonists Restore Cortical Plasticity in Patients with Idiopathic Restless Legs Syndrome |
000F09 |
Akiyuki Uzawa [Japon] ; Masahiro Mori [Japon] ; Shigeyuki Kojima [Japon] ; Satsuki Mitsuma [Japon] ; Yukari Sekiguchi [Japon] ; Toshihide Kanesaka [Japon] ; Satoshi Kuwabara [Japon] | Dopamine Agonist-induced Antecollis in Parkinson's Disease |
000F58 |
Frank Andersohn [Allemagne] ; Edeltraut Garbe [Allemagne] | Cardiac and Noncardiac Fibrotic Reactions Caused by Ergot-and Nonergot-Derived Dopamine Agonists |
000F60 |
Louis C. S. Tan [Singapour, États-Unis] ; Kenneth K. C. Ng [Singapour] ; Wing-Lok Au [Singapour, États-Unis] ; Raymond K. K. Lee [Singapour] ; Yiong-Huak Chan [Singapour] ; Nigel C. K. Tan [Singapour] | Bromocriptine Use and the Risk of Valvular Heart Disease |
000F85 |
Kelly E. Lyons [États-Unis] ; Rajesh Pahwa [États-Unis] | An Open-Label Conversion Study of Pramipexole to Ropinirole Prolonged Release in Parkinson's Disease |
001008 |
Connie Marras [Canada] ; Anthony E. Lang [Canada] ; Shirley W. Eberly [États-Unis] ; David Oakes [États-Unis] ; Stanley Fahn [États-Unis] ; Steven R. Schwid [États-Unis] ; Christopher Hyson [Canada] ; Ira Shoulson [États-Unis] | A Comparison of Treatment Thresholds in Two Large Parkinson's Disease Clinical Trial Cohorts |
001034 |
Fabrizio Stocchi [Italie] ; Michele Tagliati [États-Unis] ; C. Warren Olanow [États-Unis] | Treatment of Levodopa-Induced Motor Complications |
001063 |
Kazuo Yamashiro [Japon] ; Miki Komine-Kobayashi [Japon] ; Taku Hatano [Japon] ; Takao Urabe [Japon] ; Hideki Mochizuki [Japon] ; Nobutaka Hattori [Japon] ; Yoshitaka Iwama [Japon] ; Hiroyuki Daida [Japon] ; Michi Sakai [Japon] ; Takeo Nakayama [Japon] ; Yoshikuni Mizuno [Japon] | The Frequency of Cardiac Valvular Regurgitation in Parkinson's Disease |
001125 |
Peter Jenner [Royaume-Uni] | Preventing and Controlling Dyskinesia in Parkinson's Disease : A View of Current Knowledge and Future Opportunities |
001197 |
Nir Giladi [Israël] | Medical Treatment of Freezing of Gait |
001206 |
Eugenia Mamikonyan [États-Unis] ; Andrew D. Siderowf [États-Unis] ; John E. Duda [États-Unis] ; Marc N. Potenza [États-Unis] ; Stacy Horn [États-Unis] ; Matthew B. Stem [États-Unis] ; Daniel Weintraub [États-Unis] | Long-Term Follow-Up of Impulse Control Disorders in Parkinson's Disease |
001407 |
Susann Junghanns [Allemagne] ; Joerg T. Fuhrmann [Allemagne] ; Gregor Simonis [Allemagne] ; Christian Oelwein [Allemagne] ; Rainer Koch [Allemagne] ; Ruth H. Strasser [Allemagne] ; Heinz Reichmann [Allemagne] ; Alexander Storch [Allemagne] | Valvular heart disease in parkinson's disease patients treated with dopamine agonists : A reader-blinded monocenter echocardiography study |
001443 |
Paolo Barone [Italie] ; Janice Lamb [Royaume-Uni] ; Amanda Ellis [Royaume-Uni] ; Zoe Clarke [Royaume-Uni] | Sumanirole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson's disease |
001454 |
Wolfgang H. Oertel [Allemagne] ; Claudia Trenkwalder [Allemagne] ; Marco Zucconi [Italie] ; Heike Benes [Allemagne] ; Diego Garcia Borreguero [Espagne] ; Claudio Bassetti [Suisse] ; Markku Partinen [Finlande] ; Luigi Ferini-Strambi [Italie] ; Karin Stiasny-Kolster [Allemagne] | State of the Art in Restless Legs Syndrome Therapy : Practice Recommendations for Treating Restless Legs Syndrome |
001477 |
Nir Giladi [Israël] ; Babak Boroojerdi [Allemagne] ; Amos D. Korczyn [Israël] ; David J. Burn [Royaume-Uni] ; Carl E. Clarke [Royaume-Uni] ; Anthony H. V. Schapira [Royaume-Uni] | Rotigotine Transdermal Patch in Early Parkinson's Disease : A Randomized, Double-Blind, Controlled Study Versus Placebo and Ropinirole |
001592 |
Gregor Simonis [Allemagne] ; Joerg T. Fuhrmann [Allemagne] ; Ruth H. Strasser [Allemagne] | Meta-analysis of heart valve abnormalities in parkinson's disease patients treated with dopamine agonists |
001634 |
Claudio Lucetti [Italie] ; Paulo Del Dotto [Italie] ; Gianna Gambaccini [Italie] ; Roberto Ceravolo [Italie] ; Chiara Logi [Italie] ; Caterina Berti [Italie] ; Giuseppe Rossi [Italie] ; Maria Cristina Bianchi [Italie] ; Michela Tosetti [Italie] ; Luigi Murri [Italie] ; Ubaldo Bonuccelli [Italie] | Influences of Dopaminergic Treatment on Motor Cortex in Parkinson Disease : A MRI/MRS Study |
001666 |
Anthony H. V. Schapira [Royaume-Uni] | Future Directions in the Treatment of Parkinson's Disease |
001688 |
Wolfgang H. Oertel [Allemagne] ; Karin Stiasny-Kolster [Allemagne] ; Bettina Bergtholdt [Allemagne] ; Yngve Hallström [Suède] ; Jaan Albo [Suède] ; Lena Leissner [Suède] ; Thomas Schindler [Allemagne] ; Juergen Koester [Allemagne] ; Juergen Reess [Allemagne] | Efficacy of pramipexole in restless legs syndrome : A six-week, multicenter, randomized, double-blind study (effect-RLS study) |
001829 |
Carlos Singer [États-Unis] ; Janice Lamb [Royaume-Uni] ; Amanda Ellis [Royaume-Uni] ; Gary Layton [Royaume-Uni] | A comparison of sumanirole versus placebo or ropinirole for the treatment of patients with early Parkinson's disease |
001846 |
Cecilia Peralta [Autriche] ; Elisabeth Wolf [Autriche] ; Hannes Alber [Autriche] ; Klaus Seppi [Autriche] ; Silvana Müller [Autriche] ; Sylvia Bosch [Autriche] ; Gregor K. Wenning [Autriche] ; Otmar Pachinger [Autriche] ; Werner Poewe [Autriche] | Valvular heart disease in Parkinson's disease vs. Controls : An echocardiographic study |
001847 |
Ji-Youn Kim [Corée du Sud] ; EUN JOO CHUNG [Corée du Sud] ; SEUNG WOO PARK [Corée du Sud] ; WON YONG LEE [Corée du Sud] | Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists |
001869 |
Alexandre Castro-Caldas [Portugal] ; Paul Delwaide [Belgique] ; Wolfgang Jost [Allemagne] ; Marcelo Merello [Argentine] ; Adrian Williams [Royaume-Uni] ; Paolo Lamberti [Italie] ; Miguel Aguilar [Espagne] ; Susanna Del Signore [France] ; Pierre Cesaro [France] | The parkinson-control study : A 1-year randomized, double- blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in parkinson's disease |
001945 |
Katherine A. Grosset [Royaume-Uni] ; Graeme Macphee [Royaume-Uni] ; Guru Pal [Royaume-Uni] ; David Stewart [Royaume-Uni] ; Andrew Watt [Royaume-Uni] ; Jim Davie [Royaume-Uni] ; D. G. Grosset [Royaume-Uni] | Problematic gambling on dopamine agonists : Not such a rarity |
001B24 |
Daniel Oved [Israël] ; Ilan Ziv [Israël] ; Therese A. Treves [Israël] ; Diana Paleacu [Israël] ; Eldad Melamed [Israël] ; Ruth Djaldetti [Israël] | Effect of dopamine agonists on fatigue and somnolence in Parkinson's disease |
001B65 |
Claudia Trenkwalder [Allemagne] ; Karin Stiasny-Kolster [Allemagne] ; Andreas Kupsch [Allemagne] ; Wolfgang H. Oertel [Allemagne] ; Juergen Koester [Allemagne] ; Juergen Reess [Allemagne] | Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome |
001B69 |
Melissa J. Nirenberg [États-Unis] ; Cheryl Waters [États-Unis] | Compulsive eating and weight gain related to dopamine agonist use |
001D23 |
Katherine L. Widnell [États-Unis] ; Cynthia Comella [États-Unis] | Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations |
001E53 |
Christopher G. Goetz [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal] | Evidence-based medical review update : Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004 |
001F83 |
Katherine Grosset [Royaume-Uni] ; Fiona Needleman [Royaume-Uni] ; Graeme Macphee [Royaume-Uni] ; Donald Grosset [Royaume-Uni] | Switching from ergot to nonergot dopamine agonists in Parkinson's disease: A clinical series and five-drug dose conversion table |
002001 |
Judit Horvath [Suisse] ; Robin D. Fross [États-Unis] ; Galit Kleiner-Fisman [Canada] ; René Lerch [Suisse] ; Hans Stalder [Suisse] ; Suzanne Liaudat [Suisse] ; William J. Raskoff [États-Unis] ; Keith D. Flachsbart [États-Unis] ; Harry Rakowski [Canada] ; Jean-Claude Pache [Suisse] ; Pierre R. Burkhard [Suisse] ; Anthony E. Lang [Canada] | Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists |
002034 |
Andrew H. Evans [Royaume-Uni] ; Regina Katzenschlager [Royaume-Uni] ; Dominic Paviour [Royaume-Uni] ; John D. O'Sullivan [Australie] ; Silke Appel [Royaume-Uni] ; Andrew D. Lawrence [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Punding in Parkinson's disease: Its relation to the dopamine dysregulation syndrome |
002061 |
Karin Stiasny-Kolster [Allemagne] ; Ralf Kohnen [Allemagne] ; Erwin Schollmayer [Allemagne] ; J. Carsten Möller [Allemagne] ; Wolfgang H. Oertel [Allemagne] | Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of Restless Legs Syndrome: A double-blind, placebo-controlled pilot study |
002234 |
Marlene Jimenez Del Rio [Colombie] ; Sonia Moreno [Colombie] ; Gloria Garcia-Ospina [Colombie] ; Omar Buritica [Colombie] ; Carlos S. Uribe [Colombie] ; Francisco Lopera [Colombie] ; Carlos Velez-Pardo [Colombie] | Autosomal recessive juvenile parkinsonism Cys212Tyr mutation in arkin renders lymphocytes susceptible to dopamine- and iron-mediated apoptosis |
002257 |
Susan Hollan [Hongrie] ; Laszlo Vecsei [Hongrie] ; D. Kalman Magyar [Hongrie] | Adverse effects of dopamine potentiation by long-term treatment with selegiline |
002422 |
David R. Lynch [États-Unis] ; P. David Mozley [États-Unis] ; Set Sokol [États-Unis] ; Nicole M. C. Maas [États-Unis] ; Laura J. Balcer [États-Unis] ; Andrew D. Siderowf [États-Unis] | Lack of effect of polymorphisms in dopamine metabolism related genes on imaging of TRODAT-1 in striatum of asymptomatic volunteers and patients with Parkinson's disease |
002666 |
Giulio Cicarelli [Italie] ; Maria Teresa Pellecchia [Italie] ; Giuseppe De Michele [Italie] ; Gilberto Pizzolato [Italie] ; Paolo Barone [Italie] | Paradoxical response to apomorphine in a case of atypical parkinsonism |
002708 |
Petr Kanovsky [République tchèque] ; Dagmar Kubova [République tchèque] ; Martin Bares [République tchèque] ; Hana Hortova [République tchèque] ; Hana Streitova [République tchèque] ; Ivan Rektor [République tchèque] ; Vladimir Znojil [République tchèque] | Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: Results of a two-year, prospective follow-up |
002765 |
J. Carsten Moller [Allemagne] ; Karin Stiasny [Allemagne] ; Volker Hargutt [Allemagne] ; Werner Cassel [Allemagne] ; Heiko Tietze [Allemagne] ; J. Hermann Peter [Allemagne] ; H.-Peter Krüger [Allemagne] ; Wolfgang H. Oertel [Allemagne] | Evaluation of sleep and driving performance in six patients with Parkinson's disease reporting sudden onset of sleep under dopaminergic medication: A pilot study |
002777 |
Guillermo Paradiso [Canada] ; Farooq Khan [Canada] ; Robert Chen [Canada] | Effects of apomorphine on flexor reflex and periodic limb movement |
002808 |
| DA agonists: ergot derivatives: Bromocriptine |
002809 |
| DA agonists: Non-Ergot derivatives: Ropinirole |
002810 |
| DA agonists: Non-Ergot derivatives: Pramipexole |
002811 |
| DA agonists: Non-Ergot derivatives: Piribedil |
002812 |
| DA agonists: Non-Ergot derivatives: Apomorphine |
002813 |
| DA agonists: Ergot derivatives: Pergolide |
002814 |
| DA agonists: Ergot derivatives: Lisuride |
002815 |
| DA agonists: Ergot derivatives: Dihydroergocryptine (DHEC) |
002816 |
| DA agonists: Ergot derivatives: Cabergoline |
002858 |
Alice J. Manson [Royaume-Uni] ; Kirsten Turner [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long-term follow-up study of 64 patients |
002863 |
| Amantadine and other antiglutamate agents |
002919 |
William Koller [États-Unis] ; Andrew Lees (neurologue) [Royaume-Uni] ; Miroslava Doder [Royaume-Uni] ; Mariese Hely [Australie] | Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations |
002930 |
Virgilio Gerald H. Evidente [Philippines] | Piribedil for restless legs syndrome: A pilot study |
002966 |
Fabrizio Stocchi [Italie] ; Laura Vacca [Italie] ; Alfredo Berardelli [Italie] ; Francesca De Pandis [Italie] ; Stefano Ruggieri [Italie] | Long-duration effect and the postsynaptic compartment : Study using a dopamine agonist with a short half-life |
002A28 |
Alberto Albanese [Italie] ; Ubaldo Bonuccelli [Italie] ; Christine Brefel [France] ; K. Ray Chaudhuri [Royaume-Uni] ; Carlo Colosimo [Italie] ; Tobias Eichhorn [Allemagne] ; Eldad Melamed [Israël] ; Pierre Pollak [France] ; Teus Van Laar [Pays-Bas] ; Mario Zappia [Italie] | Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease |
002A78 |
C. W. Olanow [États-Unis] ; A. H. V. Schapira [Royaume-Uni] ; T. Roth [États-Unis] | Waking up to sleep episodes in Parkinson's disease |
002B03 |
C. Ramaker [Pays-Bas] ; W. J. T. Van De Beek [Pays-Bas] ; M. J. J. Finken [Pays-Bas] ; B. J. J. Van Hilten [Pays-Bas] | The efficacy and safety of adjunct bromocriptine therapy for levodopa-induced motor complications : A systematic review |
002B13 |
S. A. Factor [États-Unis] ; D. L. Brown [États-Unis] ; E. S. Molho [États-Unis] | Subcutaneous apomorphine injections as a treatment for intractable pain in Parkinson's disease |
002B69 |
Robert A. Hauser [États-Unis] ; Mervat N. Wahba [États-Unis] ; Theresa A. Zesiewicz [États-Unis] ; W. Mcdowell Anderson [États-Unis] | Modafinil treatment of pramipexole-associated somnolence |
002C10 |
Sarah A. Treseder [Royaume-Uni] ; Lance A. Smith [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Endogenous dopaminergic tone and dopamine agonist action |
002C52 |
E. Luginger [Autriche] ; G. K. Wenning [Autriche] ; S. Bosch [Autriche] ; Werner Poewe [Autriche] | Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's Disease |
002C57 |
Werner Poewe [Autriche] ; Gregor K. Wenning [Autriche] | Apomorphine : An underutilized therapy for Parkinson's disease |
002C98 |
S. A. Factor [États-Unis] ; E. S. Molho [États-Unis] | Transient benefit of amantadine in Parkinson's disease : The facts about the myth |
002D27 |
W. Ondo [États-Unis] ; MD [États-Unis] | Ropinirole for restless legs syndrome |
002D60 |
L. E. Davis [États-Unis] ; J. C. Adair [États-Unis] | Parkinsonism from methanol poisoning : Benefit from treatment with anti-Parkinson drugs |
002E11 |
M. Merello [Argentine] ; Andrew Lees (neurologue) [Royaume-Uni] ; J. Balej [Argentine] ; A. Cammarota [Argentine] ; R. Leiguarda [Argentine] | GPi firing rate modification during beginning-of-dose motor deterioration following acute administration of apomorphine |
002E24 |
| Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated Parkinsonian patients |
002E66 |
M. Merello [Argentine] ; J. Balej [Argentine] ; M. Delfino [Argentine] ; A. Cammarota [Argentine] ; O. Betti [Argentine] ; R. Leiguarda [Argentine] | Apomorphine induces changes in GPi spontaneous outflow in patients with Parkinson's disease |
003085 |
P. J. Blanchet [États-Unis] ; S. Konitsiotis [États-Unis] ; T. N. Chase [États-Unis] | Amantadine reduces levodopa-induced dyskinesias in Parkinsonian monkeys |
003397 |
G. Geminiani [Italie] ; V. Fetoni [Italie] ; S. Genitrini [Italie] ; P. Giovannini [Italie] ; F. Tamma [Italie] ; T. Caraceni [Italie] | Cabergoline in Parkinson's disease complicated by motor fluctuations |
003564 |
R. J. Vermeulen [Pays-Bas] ; B. Drukarch [Pays-Bas] ; M. C. R. Sahadat ; C. Goosen ; E. C. Wolters [Pays-Bas] ; J. C. Stoof [Pays-Bas] | The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian rhesus monkeys |
003662 |
D. Bravi [États-Unis] ; T. L. Davis ; M. M. Mouradian ; T. N. Chase | Treatment of Parkinson's disease with the partial dopamine agonist EMD 49980 |
003800 |
J.-F. De Saint Victor [France] ; C.-L. Gervason | Levopoda-induced diphasic dyskinesias improved by subcutaneous apomorphine |
003807 |
S. Przedborski [Belgique] ; A. Liard ; J. Hildebrand | Induction of mania by apomorphine in a depressed Parkinsonian patient |
003818 |
M. Emre [Suisse] ; U. K. Rinne ; A. Rascol ; A. Lees ; Yves Agid [France] ; X. Lataste | Effects of a selective partial D1 agonist, CY 208-243, in De Novo patients with Parkinson disease |
003820 |
D. Bravi [États-Unis] ; J. J. Anderson ; F. Dagani ; T. L. Davis ; R. Feerari ; M. Gillespie ; T. N. Chase | Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease |
003821 |
B. Gomez-Mancilla [Canada] ; R. Boucher ; P. J. Bedard | Effect of LY 171555 and CY 208-243 on tremor suppression in the MPTP monkey model of Parkinsonism |
003904 |
S. T. Gancher ; J. G. Nutt ; W. R. Woodward | Absorption of apomorphine by various routes in parkinsonism |
003920 |
J. M. Cedarbaum ; M. Clark ; L. H. Toy ; A. Green-Parsons | Sustained-release (+)-PHNO [MK-458 (HPMC)] in the treatment of Parkinson's disease : evidence for tolerance to a selective D2-receptor agonist administered as a long-acting formulation |
003936 |
M. E. Rodriguez ; M. R. Luquin ; G. Lera ; G. Delgado ; J. M. Salazar ; J. A. Obeso | Neuroleptic malignant syndrome treated with subcutaneous lisuride infusion |
003943 |
S. Boyce ; C. E. Clarke ; R. Luquin ; D. Peggs ; R. G. Robertson ; I. J. Mitchell ; M. A. Sambrook ; A. R. Crossman | Induction of chorea and dystonia in parkinsonian primates |
003955 |
J. Vaamonde ; M. R. Luquin ; J. A. Obeso | Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease |
003966 |
Werner Poewe [Autriche] ; G. Luef ; B. Kleedorfer ; M. Emre | Antiparkinsonian activity of a non-ergot dopamine agonist, CV 205-502, in patients with fluctuating Parkinson's disease |
003972 |
A. R. Crossman | A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment |
003986 |
R. J. Coleman ; K. W. Lange ; N. P. Quinn ; A. E. Loper ; J. V. Bondi ; M. Hitchens ; S. M. Stahl ; C. D. Marsden | The antiparkinsonian actions and pharmacokinetics of transdermal (+)-4-propyl-9-hydroxynaphthoxazine (+ PHNO): preliminary results |
003997 |
P. A. Kempster ; Andrew Lees (neurologue) [Royaume-Uni] ; P. Crichton ; J. P. Fkankel ; P. Shorvon | Off-period belching due to a reversible disturbance of oesophageal motility in Parkinson's disease and its treatment with apomorphine |
003A14 |
R. F. Pfeiffer ; L. H. Herrera ; C. S. Glaeske ; R. E. Hofman | CQP A01-403 in Parkinson's disease: an open-label pilot study |
003A18 |
J. A. Temlett ; N. P. Quinn ; P. G. Jenner ; C. D. Marsden ; E. Pourcher ; A.-M. Bonnet ; Y. Acid ; R. Markstein ; X. Lataste | Antiparkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease |
003A68 |
J. G. De Yebenes ; S. Fahn ; V. Jackson-Lewis ; M.-A. Mena | The effect of intracerebroventricular infusion of (+)-4-propyl-9-hydroxynapthoxacine (PHNO) through a totally implanted drug delivery system in rats with dopamine deficiency |
003A90 |
J. G. De Yebenes ; S. Fahn ; S. Lovelle ; V. Jackson-Lewis ; P. Jorge ; M. A. Mena ; J. Reiriz ; J. C. Bustos ; C. Magarinos ; A. Martinez | Continuous intracerebroventricular infusion of dopamine and dopamine agonists through a totally implanted drug delivery system in animal models of Parkinson's disease |
003A96 |
F. Grandas ; N. Quinn ; P. Critchley ; A. Rohan ; C. D. Marsden ; S. M. Stahl | Antiparkinsonian activity of a single oral dose of PHNO |
003A97 |
N. Nomoto ; S. Stahl ; P. Jenner ; C. D. Marsden | Antiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset |